Emerging Role of Endoglin (CD105) as a Marker of Angiogenesis with Clinical Potential in Human Malignancies

Current Cancer Drug Targets

Volumn 3, Issue 6, 2003, Pages 427-432

  Fonsatti, E ^a   Sigalotti, L ^a   Arslan, P ^b   Altomonte, M ^a   Maio, M ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CELL MEMBRANE PROTEIN; CYTOKINE; ENDOGLIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

ANGIOGENESIS; CANCER THERAPY; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STRUCTURE ANALYSIS; TISSUE DISTRIBUTION; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0346251249     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009033481741     Document Type: Review

References (82)

1. Griffioen, A. W.; Molema, G. Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation. Pharmacol. Rev. 2000, 52, 237-268.
2. Carmeliet, P.; Jain R. K. Angiogenesis in Cancer and Other Diseases. Nature 2000, 407, 249-257.
3. Hansen, S.; Overgaard, J.; Rose, C.; Knoop, A.; Laenkholm, A. V.; Andersen, J.; Sorensen, F. B.; Andreasen, P.A. Independent Prognostic Value of Angiogenesis and the Level of Plasminogen Activator Inhibitor Type 1 in Breast Cancer Patients. Br. J. Cancer 2003, 88, 102-108.
4. Jaeger, T. M.; Weidner, N.; Chew, K.; Moore, D. H.; Kerschmann, R. L.; Waldman, F. M.; Carrol, P. R. Tumor Angiogenesis Correlates with Lymph Node Metastases in Invasive Bladder Cancer. J. Urol. 1995, 154, 69-71.
5. Scappaticci, F. A. Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies. J. Clin. Oncol. 2002, 20, 3906-3927.
6. Rajkumar, S. V.; Mesa, R. A.; Tefferi, A. A Review of Angiogenesis and Antiangiogenic Therapy in Hematologic Malignancies. J. Hematother. Stem Cell Res. 2002, 11, 33-47.
7. Maio, M.; Altomonte, M.; Calabrò, L.; Fonsatti, E. Bioimmunotherapeutic Targets on Angiogenetic Blood Vessels in Solid Malignancies. Front. Biosci. 2001, 6, D776-784.
8. Thorpe, P. E.; Burrows F. J. Antibody-Directed Targeting of the Vasculature of Solid Tumors. Breast Cancer Res. Treat. 1995, 36, 237-251.
9. Gougos, A.; Letarte M. Identification of a Human Endothelial Cell Antigen with Monoclonal Antibody 44G4 Produced Against a Pre-B Leukemic Cell Line. J. Immunol. 1988, 141, 1925-1933.
10. Gougos, A.; Letarte, M. Primary Structure of Endoglin, an RGD-Containing Glycoprotein of Human Endothelial Cells. J. Biol. Chem. 1990, 265, 8361-8364.
11. Bellón, T.; Corbi, A.; Lastres, P.; Calés, C.; Cebrian, M. ; Vera, S.; Cheifetz, S.; Massagué, J.; Letarte, M.; Bernabéu, C. Identification and Expression of Two Forms of the Human Transforming Growth Factor-Beta-Binding Protein Endoglin with Distinct Cytoplasmic Regions. Eur. J. Immunol. 1993, 23, 2340-2345.
12. Cheifetz, S.; Bellón, T.; Calés, C.; Vera, S.; Bernabéu, C.; Massagué, J.; Letarte, M. Endoglin is a Component of the Transforming Growth Factor-β Receptor System in Human Endothelial Cells. J. Biol. Chem. 1992, 267, 19027-19030.
13. Lastres, P.; Martin-Perez, J.; Langa, C.; Bernabéu, C. Phosphorylation of the Human Transforming Growth Factor-β Binding Protein Endoglin. Biochem. J. 1994, 301, 765-768.
14. Ge, A. Z.; Butcher, E. C. Cloning and Expression of a cDNA Encoding Mouse Endoglin, an Endothelial Cell TGF-Beta Ligand. Gene 1994, 138, 201-206.
15. Yamashita, H.; Ichijo, H.; Grimsby, S.; Morén, A.; ten Dijke, P.; Miyazono, K. Endoglin Forms a Heteromeric Complex with the Signaling Receptors for Transforming Growth Factor-β. J. Biol. Chem. 1994, 269, 1995-2001.
16. Fernandez-Ruiz, E.; St-Jacques, S.; Bellon, T.; Letarte, M.; Bernabeu, C. Assignment of the Human Endoglin Gene (END) to 9q34→qter. Cytogenet. Cell Genet. 1993, 64, 204-207.
17. McAllister, K. A.; Baldwin, M. A.; Thukkani, A. K.; Gallione, C. J.; Berg, J. N.; Porteous, M. E.; Guttmacher, A. E.; Marchuk, D. A. Six Novel Mutations in the Endoglin Gene in Hereditary Hemorrhagic Telangiectasia Type 1 Suggest a Dominant-Negative Effect of Receptor Function. Hum. Mol. Genet. 1995, 4, 1983-1985.
18. Burrows, F. J.; Derbyshire, E. J.; Tazzari, P. L.; Amlot, P.; Gazdar, A. F.; King, S. W.; Letarte, M.; Vitetta, E. S.; Thorpe P. E. Up-Regulation of Endoglin on Vascular Endothelial Cells in Human Solid Tumors: Implications for Diagnosis and Therapy. Clin. Cancer Res. 1995, 1, 1623-1634.
19. Graulich, W.; Nettelbeck, D. M.; Fischer, D.; Kissel, T.; Muller, R. Cell Type Specificity of the Human Endoglin Promoter. Gene. 1999, 227, 55-62.
20. Ríus, C.; Smith, J. D.; Almendro, N.; Langa, C.; Botella, L. M.; Marchuk, D. A.; Vary, C. P. H.; Bernabéu, C. Cloning of the Promoter Region of Human Endoglin, the Target Gene for Hereditary Hemorrhagic Telangiectasia Type 1. Blood 1998, 92, 4677-4690.
21. Botella, L. M.; Sanchez-Elsner, T.; Rius, C.; Corbi, A.; Bernabéu, C. Identification of a Critical Sp1 Site within the Endoglin Promoter and Its Involvement in the Transforming Growth Factor-Beta Stimulation. J. Biol. Chem. 2001, 276, 34486-34494.
22. Botella, L. M.; Sanchez-Elsner, T.; Sanz-Rodriguez, F.; Kojima, S.; Shimada, J.; Guerrero-Esteo, M.; Cooreman, M. P.; Ratziu, V.; Langa, C.; Vary, C. P.; Ramirez, J. R.; Friedman, S.; Bernabéu, C. Transcriptional Activation of Endoglin and Transforming Growth Factor-Beta Signaling Components by Cooperative Interaction between Sp1 and KLF6: Their Potential Role in the Response to Vascular Injury. Blood 2002,100, 4001-4010.
23. Wang, J. M.; Kumar, S.; Pye, D.; van Agthoven, A. J.; Krupinski, J.; Hunter, R. D. A Monoclonal Antibody Detects Heterogeneity in Vascular Endothelium of Tumours and Normal Tissues. Int. J. Cancer 1993, 54, 363-370.
24. Miller, D. W.; Graulich, W.; Karges, B.; Stahl, S.; Ernst, M.; Ramaswamy, A.; Sedlacek, H. H.; Müller, R.; Adamkiewicz, J. Elevated Expression of Endoglin, a Component of the TGF-β-Receptor Complex, Correlates with Proliferation of Tumor Endothelial Cells. Int. J. Cancer 1999, 81, 568-572.
25. Lastres, P.; Bellón, T.; Cabañas, C.; Sanchez-Madrid, F.; Acevedo, A.; Gougos, A.; Letarte, M.; Bernabéu, C. Regulated Expression on Human Macrophages of Endoglin, an Arg-Gly-Asp-Containing Surface Antigen. Eur. J. Immunol. 1992, 22, 393-397.
26. Rokhlin, O. W.; Cohen, M. B.; Kubagawa, H.; Letarte, M.; Cooper, M. D. Differential Expression of Endoglin on Fetal and Adult Hematopoietic Cells in Human Bone Marrow. J. Immunol. 1995, 154, 4456-4465.
27. Robledo, M. M.; Hidalgo, A.; Lastres, P.; Arroyo, A. G.; Bernabéu, C.; Sanchez-Madrid, F.; Teixido, J. Characterization of TGF-β1 Binding Proteins in Human Bone Marrow Stromal Cells. Br. J. Haematol. 1996, 93, 507-514.
28. Cho, S. K.; Bourdeau, A.; Letarte, M.; Zúñiga-Pflücker, J. C. Expression and Function of CD105 during the Onset of Hematopoiesis from Flkl+ Precursors. Blood 2001, 98, 3635-3642.
29. O'Connell, P. J.; McKenzie, A.; Fisicaro, N.; Rockman, S. P.; Pearse, M. J.; d'Apice, A. J. F. Endoglin: a 180-kD Endothelial Cell and Macrophage Restricted Differentiation Molecule. Clin. Exp. Immunol. 1992, 90, 154-159.
30. Adam, P. J.; Clesham, G. J.; Weissberg, P. L. Expression of Endoglin mRNA and Protein in Human Vascular Smooth Muscle Cells. Biochem. Biophys. Res. Commun. 1998, 247, 33-37.
31. Diez-Marques, L.; Ortega-Velazquez, R.; Langa, C.; Rodriguez-Barbero A.; Lopez-Novoa, J. M.; Lamas, S.; Bernabéu, C. Expression of Endoglin in Human Mesangial Cells: Modulation of Extracellular Matrix Synthesis. Biochim. Biophys. Acta 2002, 1587, 36-44.
32. Wong, S. H.; Hamel, L.; Chevalier, S.; Philip, A. Endoglin Expression On Human Microvascular Endothelial Cells Association With Betaglycan and Formation of Higher Order Complexes with TGF-Beta Signalling Receptors. Eur. J. Biochem. 2000, 267, 5550-5560.
33. Hirakawa, S.; Hong, Y. K.; Harvey, N.; Schacht, V.; Matsuda, K.; Libermann, T.; Detmar, M. Identification of Vascular Lineage-Specific Genes by Transcriptional Profiling of Isolated Blood Vascular and Lymphatic Endothelial Cells. Am. J. Pathol. 2003, 162, 575-586.
34. Fonsatti, E.; Del Vecchio, L.; Altomonte, M.; Sigalotti, L.; Nicotra, M. R.; Coral, S.; Natali, P. G.; Maio, M. Endoglin: An Accessory Component of the TGF-Beta Binding Receptor-Complex with Diagnostic, Prognostic, and Bioimmunotherapeutic Potential in Human Malignancies. J. Cell Physiol. 2001, 188, 1-7.
35. Henriksen, R.; Gobl, A.; Wilander, E.; Oberg, K.; Miyazono, K.; Funa, K. Expression and Prognostic Significance of TGF-Beta Isotypes, Latent TGF-Beta 1 Binding Protein, TGF-Beta Type I and Type 11 Receptors, and Endoglin in Normal Ovary And Ovarian Neoplasms. Lab. Invest. 1995, 73, 213-220.
36. Fonsatti, E.; Jekunen, A. P.; Kairemo, K. J.; Coral, S.; Snellman, M.; Nicotra, M. R.; Natali, P. G.; Altomonte, M.; Maio, M. Endoglin is a Suitable Target for Efficient Imaging of Solid Tumors: In Vivo Evidence in a Canine Mammary Carcinoma Model. Clin. Cancer Res. 2000, 6, 2037-2043.
37. Altomonte, M.; Montagner, R.; Fonsatti, E.; Colizzi, F.; Cattarossi, I.; Brasoveanu, L. I.; Nicotra, M. R.; Cattelan, A.; Natali, P. G.; Maio, M. Expression and Structural Features of Endoglin (CD105), A Transforming Growth Factor Betal and Beta3 Binding Protein, in Human Melanoma. Br. J. Cancer 1996, 74, 1586-1591.
38. Lo Pardo, C.; Altomonte, M.; Boccuni, P.; Di Noto, R.; Vacca, C.; Maio, M.; Del Vecchio, L. In Leucocyte typing VI. White Cell Differentiation Antigens: CD105 Workshop: Expression of CD105 on Acute Leukemia Blast Cells: Application for Minimal Residual Disease Detection; Kishimoto, T.; Kikutani, H.; Von dem, Kr.; Borne, A. E. G.; Goyert, S. M.; Mason, D. Y.; Miyasaka, M.; Moretta, L.; Okumura, K.; Shaw, S.; Springer, T. A.; Sugamura, K.; Zola, H., Eds. Garland Publishing, Inc.: New York, London, 1997, pp 711-712
39. Haruta, Y.; Seon, B. K. Distinct Human Leukaemia-Associated Cell Surface Glycoprotein GP160 Defined by Monoclonal Antibody SN6. Proc. Natl. Acad Sci. USA 1986, 83, 7898-7902.
40. Blobe, G. C.; Schiemann, W. P.; Lodish, H. F. Role of Transforming Growth Factor Beta in Human Disease. N. Engl. J. Med. 2000, 342, 1350-1358.
41. Zhu, H. J.; Burgess, A. W. Regulation of Transforming Growth Factor-Beta Signaling. Mol. Cell. Biol. Res. Commun. 2001, 4, 321-330.
42. Lastres, P.; Letamendia, A.; Zhang, H.; Ríus, C.; Almendro, N.; Raab, U.; López, L. A.; Langa, C.; Fabra, A.; Letarte, M.; Bernabéu, C. Endoglin Modulates Cellular Response to TGF-β1. J. Cell Biol. 1996, 133, 1109-1121.
43. Barbara, N. P.; Wrana, J. L.; Letarte, M. Endoglin is an Accessory Protein that Interacts with the Signaling Receptor Complex of Multiple Members of the Transforming Growth Factor-β superfamily. J. Biol. Chem. 1999, 274, 584-594.
44. Letamendia, A.; Lastres, P.; Botella, L. M.; Raab, U.; Langa, C.; Velasco, B.; Attisano, L.; Bernabéu, C. Role of Endoglin in Cellular Responses to Transforming Growth Factor-β. J. Biol. Chem. 1998, 273, 33011-33019.
45. Li, C.; Hampson, I. N.; Hampson, L.; Kumar, P.; Bernabéu, C.; Kumar, S. CD105 Antagonizes the Inhibitory Signaling of Transforming Growth Factor β1 on Human Vascular Endothelial Cells. FASEB J. 2000, 14, 55-64.
46. Ma, X.; Labinaz, M.; Goldstein, J.; Millere, H.; Keon, W. J.; Letarte, M.; O'Brien, E. Endoglin is Overexpressed after Arterial Injury and is Required for Transforming Growth Factor-β-Induced Inhibition of Smooth Muscle Cell Migration. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 2546-2552.
47. Guerrero-Esteo, M.; Sanchez-Elsner, T.; Letamendía, A.; Bernabéu, C. Extracellular and Cytoplasmic Domains of Endoglin Interact with the Transforming Growth Factor-Beta Receptors I and II. J. Biol. Chem. 2002, 277, 29197-29209.
48. Shovlin, C. L.; Hughes, J. M.; Scott, J.; Seidman, C. E.; Seidman, J. G. Characterization of Endoglin and Identification of Novel Mutations in Hereditary Hemorrhagic Telangiectasia. Am. J. Hum. Genet. 1997, 61, 68-79.
49. Pece, N.; Vera, S.; Cymerman, U.; White, R. I. Jr. Wrana, J. L.; Letarte, M. Mutant Endoglin In Hereditary Hemorrhagic Telangiectasia Type 1 is Transiently Expressed Intracellularly and is Not a Dominant Negative. J. Clin. Invest. 1997, 100, 2568-2579.
50. Paquet, M. E.; Pece-Barbara, N.; Vera, S.; Cymerman, U.; Karabegovic, A. ; Shovlin, C.; Letarte, M. Analysis of Several Endoglin Mutants Reveals No Endogenous Mature or Secreted Protein Capable of Interfering with Normal Endoglin Function. Hum. Mol. Genet. 2001, 10, 1347-1357.
51. Bourdeau, A.; Dumont, D. J.; Letarte, M. A Murine Model of Hereditary Hemorrhagic Telangiectasia. J. Clin. Invest. 1999, 104, 1343-1351.
52. Li, D. Y.; Sorensen, L. K.; Brooke, B. S.; Urness, L. D.; Davis, E. C.; Taylor, D. G.; Boak, B. B.; Wendel, D. P. Defective Angiogenesis in Mice Lacking Endoglin. Science 1999, 284, 1534-1537.
53. Dickson, M. C.; Martin, J. S.; Cousins, F. M.; Kulkarni, A. B.; Karlsson, S.; Akhurst, R. J. Defective Haematopoiesis and Vasculogenesis in Transforming Growth Factor-Beta 1 Knock Out Mice. Development 1995, 121, 1845-54.
54. Bourdeau, A.; Faughnan, M. E.; McDonald, M. L.; Paterson, A. D.; Wanless, I. R.; Letarte, M. Potential Role of Modifier Genes Influencing Transforming Growth Factor-Betal Levels in the Development of Vascular Defects in Endoglin Heterozygous Mice with Hereditary Hemorrhagic Telangiectasia. Am. J. Pathol. 2001, 158, 2011-2020.
55. Ota, T. M; Fujii, M.; Sugizaki, T.; Ishii, M.; Miyazawa, K.; Aburatani, H.; Miyazono, K. Targets of Transcriptional Regulation by Two Distinct Type I Receptors for Transforming Growth Factor-Beta in Human Umbilical Vein Endothelial Cells. J. Cell Physiol. 2002, 193, 299-318.
56. Abdalla, S. A.; Pece-Barbara, N.; Vera, S.; Tapia, E.; Paez, E.; Bernabeu, C.; Letarte, M. Analysis of ALK-1 and Endoglin In Newborns from Families with Hereditary Hemorrhagic Telangiectasia Type 2. Hum. Mol. Genet. 2000, 9, 1227-1237.
57. Urness, L. D.; Sorensen, L. K.; Li, D. Y. Arteriovenous Malformations in Mice Lacking Activin Receptor-Like Kinase-1. Nat. Genet. 2000, 26, 328-331.
58. Roelen, B. A.; van Rooijen, M. A.; Mummery, C. L. Expression of ALK-1, a Type I Serine/Threonine Kinase Receptor, Coincides with Sites of Vasculogenesis And Angiogenesis in Early Mouse Development. Dev. Dyn. 1997, 209, 418-430.
59. Jonker, L.; Arthur, H. M. Endoglin Expression in Early Development is Associated With Vasculogenesis and Angiogenesis. Mech. Dev. 2002, 110, 193-196.
60. Qu, R.; Silver, M. M.; Letarte, M. Distribution of Endoglin in Early Human Development Reveals High Levels on Endocardial Cushion Tissue Mesenchyme During Valve Formation. Cell Tissue Res. 1998, 292, 333-343.
61. Wang, J. M.; Kumar, S.; Pye, D.; Haboubi, N.; Al-Nakib, L. Breast Carcinoma: Comparative Study of Tumor Vasculature Using Two Endothelial Cell Markers. J. Natl. Cancer Inst. 1994, 86, 386-388.
62. Krupinski, J.; Kaluza, J.; Kumar, P.; Kumar, S.; Wang, J. M. Role of Angiogenesis in Patients with Cerebral Ischemic Stroke. Stroke 1994, 25, 1794-1798.
63. Schimming, R.; Marme, D. Endoglin (CD105) Expression in Squamous Cell Carcinoma of the Oral Cavity. Head Neck 2002, 24, 151-156.
64. Sanchez-Elsner, T.; Botella, L. M.; Velasco, B.; Langa, C.; Bernabéu C. Endoglin Expression is Regulated by Transcriptional Cooperation between the Hypoxia and Transforming Growth Factor-Beta Pathways. J. Biol. Chem. 2002, 277, 43799-43808.
65. Kumar, S.; Ghellal, A.; Li, C.; Byrne, G.; Haboubi, N.; Wang, J. M.; Bundred, N. Breast Carcinoma: Vascular Density Determined Using CD105 Antibody Correlates with Tumor Prognosis. Cancer Res. 1999, 59, 856-861.
66. Wikstrom, P.; Lissbrant, I. F.; Stattin, P.; Egevad, L.; Bergh, A. Endoglin (CD105) is Expressed on Immature Blood Vessels and is a Marker for Survival in Prostate Cancer. Prostate 2002, 51, 268-275.
67. Brewer, C. A.; Setterdahl, J. J.; Li, M. J.; Johnston, J. M.; Mann, J. L.; McAsey, M. E. Endoglin Expression as a Measure of Microvessel Density in Cervical Cancer. Obstet. Gynecol. 2000, 96, 224-228.
68. Tanaka, F.; Otake, Y.; Yanagihara, K.; Kawano, Y.; Miyahara, R.; Li, M.; Yamada, T.; Hanaoka, N.; Inui, K.; Wada, H. Evaluation of Angiogenesis in Non-Small Cell Lung Cancer: Comparison between Anti-CD34 Antibody and Anti-CD105 Antibody. Clin. Cancer Res. 2001, 7, 3410-3415.
69. Akagi, K.; Ikeda, Y.; Sumiyoshi, Y.; Kimura, Y.; Kinoshita, J.; Miyazaki, M.; Abe, T. Estimation of Angiogenesis With Anti-CD105 Immunostaining in the Process of Colorectal Cancer Development. Surgery 2002, 131, S109-S113.
70. Pruneri, G.; Bertolini, F.; Baldini, L.; Valentini, S.; Goldaniga, M.; Soligo, D.; Carboni, N.; Viale, G.; Lambertenghi-Deliliers, G. Angiogenesis Occurs in Hairy Cell Leukaemia (HCL) and in NOD/SCID Mice Transplanted with the HCL Line Bonna-12. Br. J. Haematol. 2003, 120, 695-698.
71. Pruneri, G.; Ponzoni, M.; Ferreri, A. J.; Decarli, N.; Tresoldi, M.; Raggi, F.; Baldessari, C.; Freschi, M.; Baldini, L.; Goldaniga, M.; Neri, A.; Carboni, N.; Bertolini, F.; Viale, G. Microvessel Density, A Surrogate Marker of Angiogenesis, is Significantly Related to Survival in Multiple Myeloma Patients. Br. J. Haematol. 2002, 118, 817-820.
72. Maier, J. A. M.; Delia, D.; Thorpe, P. E.; Gasparini, G. In Vitro Inhibition of Endothelial Cell Growth by the Antiangiogenetic Drug AGM-1470 (TNP-470) and the Anti-Endoglin Antibody TEC-11. Anti-Cancer Drugs 1997, 8, 238-244.
73. Bredow, S.; Lewin, M.; Hofmann, B.; Marecos, E.; Weissleder, R. Imaging of Tumour Neovasculature by Targeting the TGF-β Binding Receptor Endoglin. Eur. J. Cancer 2000, 36, 675-681.
74. Seon, B. K.; Matsuno, F.; Haruta, Y.; Kondo, M.; Barcos, M. Long-Lasting Complete Inhibition of Human Solid Tumors in SC1D Mice by Targeting Endothelial Cells of Tumor Vasculature with Antihuman Endoglin Immunotoxin. Clin. Cancer Res. 1997, 3, 1031-1044.
75. Matsuno, F.; Haruta, Y.; Kondo, M.; Tsai, H.; Barcos, M.; Seon, B. K. Induction of Lasting Complete Regression of Preformed Distinct Solid Tumors by Targeting the Tumor Vasculature Using Two New Anti-Endoglin Monoclonal Antibodies. Clin. Cancer Res. 1999, 5, 371-382.
76. 125I-Labeled Anti-Endoglin Monoclonal Antibodies. Int. J. Cancer 1999, 82, 737-742.
77. Takahashi, N.; Haba, A.; Matsuno, F.; Seon, B. K. Antiangiogenic Therapy of Established Tumors in Human Skin/Severe Combined Immunodeficiency Mouse Chimeras by Anti-Endoglin (CD105) Monoclonal Antibodies, and Synergy between Anti-Endoglin Antibody and Cyclophosphmide. Cancer Res. 2001, 61, 7846-7854.
78. Savontaus, M. J.; Sauter, B. V.; Huang, T. G.; Woo, S. L. Transcriptional Targeting of Conditionally Replicating Adenovirus to Dividing Endothelial Cells. Gene Ther. 2002, 9, 972-979.
79. Li, C.; Guo, B.; Wilson, P. B.; Stewart, A.; Byrne, G.; Bundred, N.; Kumar, S. Plasma Levels of Soluble CD105 Correlate with Metastasis in Patients with Breast Cancer. Int. J. Cancer 2000, 89, 122-126.
80. Takahashi, N.; Kawanishi-Tabata, R.; Haba, A.; Tabata, M.; Haruta, Y.; Tsai, H.; Seon, B. K. Association of Serum Endoglin with Metastasis in Patients with Colorectal, Breast, and Other Solid Tumors, and Suppressive Effect of Chemotherapy on the Serum Endoglin. Clin. Cancer Res. 2001, 7, 524-532.
81. Calabrò, L.; Fonsatti, E.; Bellomo, G.; Alonci, A.; Colizzi, F.; Sigalotti, L.; Altomonte, M.; Musolino, C.; Maio, M. Differential Levels of Soluble Endoglin (CD105) in Myeloid Malignancies. J. Cell Physiol. 2003, 194, 171-175.
82. Seon, B. K. Expression of Endoglin (CD105) in Tumor Blood Vessels. Int. J. Cancer 2002, 99, 310-311.